Archive

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more

Houston (TX, USA) and Garching (Germany), July 26, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a group of specialized…

Read more

Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617

Read more

Bruce Power to secure global supply of no-carrier-added Lutetium-177 through 2064.

ITM to achieve new scalability of n.c.a Lutetium-177…

Read more

Recruitment in the U.S. for the COMPETE trial to begin shortly.

Solucin® studied as a first-line therapy.

Exclusively-produced…

Read more

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the appointment of Philip E. Harris, BSc MB…

Read more

ITM receives marketing authorization for a ready-to-use radiopharmaceutical in 3 European countries. TOCscan® will be the companion diagnostic in…

Read more

Acknowledgement of ITM’s success in bringing a new promising therapy in Precision Oncology to market and to the patients

Read more

Mit der Unterstützung der Initiative „Diversity als Chance – die Charta der Vielfalt der Unternehmen in Deutschland“ setzt ITM Isotopen Technologien…

Read more

Endocyte, Inc., and ITM Isotopen Technologien München AG (ITM) today announced a supply agreement under which ITM will supply to Endocyte the medical…

Read more